GENEVA (AP) — Swiss drug maker Roche Holding AG has ended development of a cholesterol drug that it had hoped could achieve blockbuster status.
Basel-based Roche announced Monday it is pulling the plug on dalcetrapib, which was in late-stage trials to study if it could increase so-called "good" cholesterol.
The company said in a statement the decision was based on the recommendation of its independent data and safety monitoring board.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
